Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients.

Koshy N, Quispe D, Shi R, Mansour R, Burton GV.

Breast. 2010 Jun;19(3):246-8. doi: 10.1016/j.breast.2010.02.003. Epub 2010 Mar 15.

PMID:
20227277
3.

Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience.

Ozkan M, Berk V, Kaplan MA, Benekli M, Coskun U, Bilici A, Gumus M, Alkis N, Dane F, Ozdemir NY, Colak D, Dikilitas M.

Neoplasma. 2012;59(1):38-42.

PMID:
22103897
4.

Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status.

Gonçalves A, Deblock M, Esterni B, Tarpin C, Bertucci F, Gilabert M, Charafe-Jauffret E, Jacquemier J, Houvenaeghel G, Extra JM, Viens P.

Anticancer Drugs. 2009 Nov;20(10):946-52. doi: 10.1097/CAD.0b013e328331178f.

PMID:
19741502
5.

Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.

Torrisi R, Balduzzi A, Ghisini R, Rocca A, Bottiglieri L, Giovanardi F, Veronesi P, Luini A, Orlando L, Viale G, Goldhirsch A, Colleoni M.

Cancer Chemother Pharmacol. 2008 Sep;62(4):667-72. Epub 2007 Dec 7.

PMID:
18064460
6.

The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy.

Zaky SS, Lund M, May KA, Godette KD, Beitler JJ, Holmes LR, O'Regan RM, Yu ES, Yu DS, Landry JC.

Ann Surg Oncol. 2011 Oct;18(10):2858-65. doi: 10.1245/s10434-011-1669-4. Epub 2011 Mar 26.

PMID:
21442346
7.

Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005.

Geiger S, Cnossen JA, Horster S, DiGioia D, Heinemann V, Stemmler HJ.

Anticancer Drugs. 2011 Oct;22(9):933-9. doi: 10.1097/CAD.0b013e32834860af.

PMID:
21666437
8.

[Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].

Zhang P, Xu BH, Ma F, Li Q, Yuan P, Wang JY, Zhang P.

Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):381-4. Chinese.

PMID:
21875471
9.

Pattern of metastatic spread in triple-negative breast cancer.

Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA.

Breast Cancer Res Treat. 2009 May;115(2):423-8. doi: 10.1007/s10549-008-0086-2. Epub 2008 Jun 10.

PMID:
18543098
10.

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO.

Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.

11.

Is conservative surgery a good option for patients with "triple negative" breast cancer?

Martinez-Ramos D, Escrig-Sos J, Torrella-Ramos A, Alcalde-Sanchez M, Salvador-Sanchis JL.

Breast. 2012 Jun;21(3):401-5. doi: 10.1016/j.breast.2012.04.005. Epub 2012 May 11.

PMID:
22579462
12.
13.

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.

Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, Fralick M, Kumar R, Clemons M.

Clin Breast Cancer. 2009 Feb;9(1):29-33. doi: 10.3816/CBC.2009.n.005.

PMID:
19299237
14.

Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients?

Erten C, Demir L, Somali I, Alacacioglu A, Kucukzeybek Y, Akyol M, Can A, Dirican A, Bayoglu V, Tarhan MO.

Asian Pac J Cancer Prev. 2013;14(6):3711-7.

16.

The prognostic importance of triple negative breast carcinoma.

Mersin H, Yildirim E, Berberoglu U, Gülben K.

Breast. 2008 Aug;17(4):341-6. doi: 10.1016/j.breast.2007.11.031. Epub 2008 May 1.

PMID:
18450442
17.

Directed therapy of subtypes of triple-negative breast cancer.

Carey LA.

Oncologist. 2011;16 Suppl 1:71-8. doi: 10.1634/theoncologist.2011-S1-71.

18.

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial.

Brufsky A, Valero V, Tiangco B, Dakhil S, Brize A, Rugo HS, Rivera R, Duenne A, Bousfoul N, Yardley DA.

Breast Cancer Res Treat. 2012 Jun;133(3):1067-75. doi: 10.1007/s10549-012-2008-6. Epub 2012 Mar 14.

PMID:
22415477
19.

Clinicopathologic and prognostic characteristics of triple-negative breast cancer.

Tian XS, Cong MH, Zhou WH, Zhu J, Chen YZ, Liu Q.

Onkologie. 2008 Nov;31(11):610-4. doi: 10.1159/000162288. Epub 2008 Oct 27.

PMID:
19145094
20.

[Effective therapeutic regimens for patients with triple-negative (ER/PgR/HER2-negative) metastatic breast cancer].

Kan N, Kuwata K, Mise K, Kodama H.

Gan To Kagaku Ryoho. 2010 Jul;37(7):1259-64. Japanese.

PMID:
20647706

Supplemental Content

Support Center